Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed against GeneDx Holdings Corp. The suit, filed in the United States District Court for the District of Connecticut, covers purchasers of WGS common stock between April 16, 2025 and May 4, 2026. The complaint alleges the company and its executives made false or misleading statements regarding the importance of Fabric Genomics, the durability of average reimbursement rates, and gross margins. On May 4, 2026, GeneDx reported a first-quarter loss of $0.28 per share and a $57.5 million operating loss, lowered its 2026 revenue guidance by approximately $65 million at the midpoint, and took a $31.3 million write-down related to Fabric Genomics. The stock fell roughly 50%, from $67.93 to $34.51, on the news. Investors have until August 3, 2026 to seek lead plaintiff appointment.
GeneDx Holdings Corp.Class action lawsuit alleging false statements, plus poor earnings and lowered guidance, causing 50% stock drop.